Weisan Chen was awarded an NHMRC Visiting Postgraduate Scholarship for Higher Degree in 1989. After acquiring his PhD in Immunology at the Flinders University of Adelaide, Australia, he was awarded a CJ Martin fellowship from NHMRC and took a postdoctoral position at the National Institutes of Health (NIH), Bethesda, Maryland, USA, in the laboratory of Drs Yewdell and Bennink. At the NIH, Dr Chen continued his studies on the mechanisms of antigen processing/presentation, immunodominance, and CD8+ T cell epitope selection. During this time, Dr Chen discovered the 11th influenza A virus gene product. He returned to Australia in 2001 to establish his independent T cell Laboratory at the Ludwig Institute, Melbourne, and was soon awarded a Wellcome senior international research fellowship from Wellcome Trust, UK. In this position, he expanded his research to include translational tumor immunology and cancer vaccines. Dr. Chen’s lab is currently focusing on innate immune cell and T cell responses to the influenza A virus. More specifically, the initiation and maintenance of anti-viral T cell response in murine models, antigen cross-presentation and immunodominance, and regulatory T cells and their function in anti-viral immunity in humans. Dr Chen’s lab is also actively involved in anti-tumor immunity and vaccine development. Dr Chen is currently a Chief Investigator on the NHMRC influenza program alongside Nobel Laureate Professor Peter Doherty.